Lercanidipine in clinical cases Case report
Article Sidebar
Published:
Mar 31, 2014
Keywords:
calcium channel blocker, arterial hypertension, treatment tolerability
Main Article Content
Abstract
Lercanidipine is a long-lasting calcium channel blocker of the dihydropiridine class. Among other drugs in this group it has advantageous profile of adverse effects. In this article are presented two patients: female already treated with amlodipine with lower limbs edema and elder female with insufficiently treated arterial hypertension. Both of them can benefit from treatment with lercanidipine.
Article Details
How to Cite
Cacko, A. (2014). Lercanidipine in clinical cases. Medycyna Faktow (J EBM), 7(1(22), 69-73. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2385
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Angelico P., Guarneri L., Leonardi A. et al.: Vascular-selective effect of lercanidipine and other 1,4-dihydropyridines in isolated rabbit tissues. J. Pharm. Pharmacol. 1999; 51(6): 709-14.
2. Herbette L.G., Vecchiarelli M., Sartani A. et al.: Lercanidipine: short plasma half-life, long duration of action and high cholesterol tolerance. Updated molecular model to rationalize its pharmacokinetic properties. Blood Press. Suppl. 1998; 2: 10-17.
3. Charakterystyka produktu leczniczego Primacor, Centrum Informacji o Leku.
4. Charakterystyka produktu leczniczego Norvasc, Centrum Informacji o Leku.
5. Borghi C., Prandin M.G., Dormi A. et al.: Improved tolerability of the dihydropyridine calcium channel antagonist lercanidipine: the lercanidipine challenge trial. Blood Press. Suppl. 2003; 1: 14-21.
6. Widecka K., Grodzicki T., Narkiewicz K. et al.: Zasady postępowania w nadciśnieniu tętniczym – 2011 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciśnienie Tętnicze 2011; 15(2): 55-82.
7. Kostowski W., Herman Z.S.: Leki β-adrenolityczne oraz leki blokujące kanały wapniowe. W: Farmakologia. Podstawy farmakoterapii. Podręcznik dla studentów medycyny i lekarzy. Kostowski W., Herman Z.S. (red.). PZWL, Warszawa 2005: 519-527.
8. Messerli F.H.: Vasodilatory edema: a common side effect of antihypertensive therapy. Curr. Cardiol. Rep. 2002; 4(6): 479-82.
9. Barrios V., Navarro A., Esteras A. et al.: Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE Study. Eficacia de Lercanidipino y su Perfil de Seguridad. Blood Press. 2002; 11(2): 95-100.
10. Barrios V., Escobar C., Navarro A. et al.: Lercanidipine is an effective and well tolerated antihypertensive drug regardless the cardiovascular risk profile: The LAURA study. Int. J. Clin. Pract. 2006; 60(11): 1364-70.
11. Cherubini A., Fabris F., Ferrari E. et al.: Comparative effects of lercanidipine, lacidipine, and nifedipine gastrointestinal therapeutic system on blood pressure and heart rate in elderly hypertensive patients: the ELderly and LErcanidipine (ELLE) study. Arch. Gerontol. Geriatr. 2003; 37(3): 203-12.
12. Leonetti G., Magnani B., Pessina A.C. et al.: Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives. Am. J. Hypertens. 2002; 15(11): 932-40.
13. Psaty B.M., Heckbert S.R., Koepsell T.D. et al.: The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995; 274: 620-625.
14. Meredith P.A. Lercanidipine: a novel lipophilic dihydropyridine calcium antagonist with long duration of action and high vascular selectivity. Expert Opin. Investig. Drugs 1999; 8(7): 1043-62.
15. Mancia G., De Backer G., Dominiczak A. et al.: 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart J. 2007; 28(12): 1462-536.
16. Beckett N.S., Peters R., Fletcher A.E. et al.: Treatment of hypertension in patients 80 years of age or older. N. Engl. J. Med. 2008; 358(18): 1887-98.
17. Dalla Vestra M., Pozza G., Mosca A. et al.: Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive Type 2 diabetic patients with microalbuminuria: DIAL study (diabete, ipertensione, albuminuria, lercanidipina). Diabetes Nutr. Metab. 2004; 17(5): 259-66.
18. Puig J.G., Calvo C., Luurila O. et al.: Lercanidipine, enalapril and their combination in the treatment of elderly hypertensive patients: placebocontrolled, randomized, crossover study with four ABPM. J. Hum. Hypertens. 2007; 21(12): 917-24.
19. James I.G., Jones A., Davies P.: A randomised, double-blind, double-dummy comparison of the efficacy and tolerability of lercanidipine tablets and losartan tablets in patients with mild to moderate essential hypertension. J. Hum. Hypertens. 2002; 16(8): 605-10.
20. Agrawal R., Marx A., Haller H.: Efficacy and safety of lercanidipine versus hydrochlorothiazide as add-on to enalapril in diabetic populations with uncontrolled hypertension. J. Hypertens. 2006; 24(1): 185-92.
2. Herbette L.G., Vecchiarelli M., Sartani A. et al.: Lercanidipine: short plasma half-life, long duration of action and high cholesterol tolerance. Updated molecular model to rationalize its pharmacokinetic properties. Blood Press. Suppl. 1998; 2: 10-17.
3. Charakterystyka produktu leczniczego Primacor, Centrum Informacji o Leku.
4. Charakterystyka produktu leczniczego Norvasc, Centrum Informacji o Leku.
5. Borghi C., Prandin M.G., Dormi A. et al.: Improved tolerability of the dihydropyridine calcium channel antagonist lercanidipine: the lercanidipine challenge trial. Blood Press. Suppl. 2003; 1: 14-21.
6. Widecka K., Grodzicki T., Narkiewicz K. et al.: Zasady postępowania w nadciśnieniu tętniczym – 2011 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciśnienie Tętnicze 2011; 15(2): 55-82.
7. Kostowski W., Herman Z.S.: Leki β-adrenolityczne oraz leki blokujące kanały wapniowe. W: Farmakologia. Podstawy farmakoterapii. Podręcznik dla studentów medycyny i lekarzy. Kostowski W., Herman Z.S. (red.). PZWL, Warszawa 2005: 519-527.
8. Messerli F.H.: Vasodilatory edema: a common side effect of antihypertensive therapy. Curr. Cardiol. Rep. 2002; 4(6): 479-82.
9. Barrios V., Navarro A., Esteras A. et al.: Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE Study. Eficacia de Lercanidipino y su Perfil de Seguridad. Blood Press. 2002; 11(2): 95-100.
10. Barrios V., Escobar C., Navarro A. et al.: Lercanidipine is an effective and well tolerated antihypertensive drug regardless the cardiovascular risk profile: The LAURA study. Int. J. Clin. Pract. 2006; 60(11): 1364-70.
11. Cherubini A., Fabris F., Ferrari E. et al.: Comparative effects of lercanidipine, lacidipine, and nifedipine gastrointestinal therapeutic system on blood pressure and heart rate in elderly hypertensive patients: the ELderly and LErcanidipine (ELLE) study. Arch. Gerontol. Geriatr. 2003; 37(3): 203-12.
12. Leonetti G., Magnani B., Pessina A.C. et al.: Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives. Am. J. Hypertens. 2002; 15(11): 932-40.
13. Psaty B.M., Heckbert S.R., Koepsell T.D. et al.: The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995; 274: 620-625.
14. Meredith P.A. Lercanidipine: a novel lipophilic dihydropyridine calcium antagonist with long duration of action and high vascular selectivity. Expert Opin. Investig. Drugs 1999; 8(7): 1043-62.
15. Mancia G., De Backer G., Dominiczak A. et al.: 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart J. 2007; 28(12): 1462-536.
16. Beckett N.S., Peters R., Fletcher A.E. et al.: Treatment of hypertension in patients 80 years of age or older. N. Engl. J. Med. 2008; 358(18): 1887-98.
17. Dalla Vestra M., Pozza G., Mosca A. et al.: Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive Type 2 diabetic patients with microalbuminuria: DIAL study (diabete, ipertensione, albuminuria, lercanidipina). Diabetes Nutr. Metab. 2004; 17(5): 259-66.
18. Puig J.G., Calvo C., Luurila O. et al.: Lercanidipine, enalapril and their combination in the treatment of elderly hypertensive patients: placebocontrolled, randomized, crossover study with four ABPM. J. Hum. Hypertens. 2007; 21(12): 917-24.
19. James I.G., Jones A., Davies P.: A randomised, double-blind, double-dummy comparison of the efficacy and tolerability of lercanidipine tablets and losartan tablets in patients with mild to moderate essential hypertension. J. Hum. Hypertens. 2002; 16(8): 605-10.
20. Agrawal R., Marx A., Haller H.: Efficacy and safety of lercanidipine versus hydrochlorothiazide as add-on to enalapril in diabetic populations with uncontrolled hypertension. J. Hypertens. 2006; 24(1): 185-92.